Jefferies Group's GLUE Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 27,506 shares of Monte Rosa Therapeutics, Inc. (GLUE) worth $452,474, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in GLUE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Monte Rosa Therapeutics (GLUE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Monte Rosa Therapeutics (GLUE) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +27,506 | New Buy | 27,506 | $16.45 |
Jefferies Group's Monte Rosa Therapeutics Investment FAQs
Jefferies Group first purchased Monte Rosa Therapeutics, Inc. (GLUE) in Q1 2026, acquiring 27,506 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Monte Rosa Therapeutics, Inc. (GLUE) for 1 quarters since Q1 2026.
Jefferies Group's largest addition to Monte Rosa Therapeutics, Inc. (GLUE) was in Q1 2026, adding 27,506 shares worth $452,474.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 27,506 shares of Monte Rosa Therapeutics, Inc. (GLUE), valued at approximately $452,474.
As of the Q1 2026 filing, Monte Rosa Therapeutics, Inc. (GLUE) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Monte Rosa Therapeutics, Inc. (GLUE) was 27,506 shares, as reported at the end of Q1 2026.